Carolyn Britten, MD

Carolyn Britten, MD

VP, Clinical Development, Solid Tumors,

BeOne

Sessions:

Speaker Next-Gen Modality Convergence: ADCs, Radiopharmaceuticals, Bispecifics, and Protein Degraders